Do inhibitors of the rennin-angiotensin system prevent chronic kidney disease?
Brian
B
Rayner
D047228:Angiotensin II Type 1 Receptor Blockers / Q000009:adverse effects / Q000627:therapeutic use*; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D003928:Diabetic Nephropathies / Q000503:physiopathology / Q000517:prevention & control; D018450:Disease Progression; D023381:Endpoint Determination; D019317:Evidence-Based Medicine; D006333:Heart Failure / Q000188:drug therapy / Q000503:physiopathology; D006801:Humans; D006973:Hypertension / Q000188:drug therapy / Q000503:physiopathology; D007674:Kidney Diseases / Q000209:etiology / Q000503:physiopathology / Q000517:prevention & control*; D017410:Practice Guidelines as Topic; D012084:Renin-Angiotensin System / Q000187:drug effects*; D016896:Treatment Outcome
D047228:Angiotensin II Type 1 Receptor Blockers; D000806:Angiotensin-Converting Enzyme Inhibitors